Status:
COMPLETED
Placental Expression of EG-VEGF and Its PROKR1 and PROKR2 Receptors in Preeclampsia Patients.
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborating Sponsors:
Commissariat A L'energie Atomique
Conditions:
Preeclampsia
Eligibility:
FEMALE
18+ years
Brief Summary
The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest th...
Eligibility Criteria
Inclusion
- All patients who have given birth by cesarean section at the maternity University Hospital Saint Etienne and all underwent a placenta pathological examination at the Saint Etienne University Hospital.
- For the pre-eclampsia group: patient with a diagnosis of pre-eclampsia
- For the control group: patient who had a normal pregnancy
Exclusion
- Patient who gave birth naturally
- Underage patients or under guardianship
- Patients who do not speak or read French
- Childbirth under X
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04846686
Start Date
June 1 2022
End Date
January 1 2023
Last Update
July 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Saint-Etienne
Saint-Etienne, France